Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 4/20 | 0.65 |
| ▸ | DRD5 | P21918 | 4/20 | 0.65 |
| ▸ | DRD4 | P21917 | 3/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | HRH1 | P35367 | 4/20 | 0.51 |
| ▸ | DRD3 | P35462 | 3/20 | 0.50 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 2/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | LTA4H | P09960 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6689247 | 0.85 | DRD1 (0.68) | DRD1DRD5DRD4ALDH1A1POLB | |
| SCHEMBL6629117 | 0.82 | DRD1 (0.59) | DRD1DRD5DRD4ALDH1A1POLB | |
| SCHEMBL20347267 | 0.80 | ALDH1A1 (0.72) | ALDH1A1POLBLTA4H | |
| SCHEMBL4024630 | 0.79 | DRD1 (0.71) | DRD1DRD5DRD4ALDH1A1POLB | |
| SCHEMBL6756721 | 0.78 | KDM4E (0.60) | DRD1DRD5DRD4ALDH1A1POLB | |
| SCHEMBL8324677 | 0.78 | L3MBTL1 (0.64) | ALDH1A1KDM4EABCB1L3MBTL1DRD2 | |
| SCHEMBL240294 | 0.77 | DRD1 (0.71) | DRD1DRD5DRD4POLBKDM4E | |
| SCHEMBL7123326 | 0.77 | DRD1 (0.71) | DRD1DRD5DRD4POLBKDM4E | |
| SCHEMBL3816351 | 0.76 | DRD1 (0.57) | DRD1DRD5DRD4ALDH1A1POLB | |
| SCHEMBL8703127 | 0.76 | DRD1 (0.74) | DRD1DRD5DRD4POLBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004096811-A1 | PDE9 INHIBITORS FOR TREATING TYPE 2 DIABETES, METABOKIC SYNDROME, AND CARDIOVASCULAR DISEASE | PFIZER PRODUCTS INC. (US) | 2004-11-11 | — | — | WO | disclosed |
| US-20040220186-A1 | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease | PFIZER INC. | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220186-A1 | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease | PDE9A, PDE2A, PDE12 | DRD1 2310/4885DRD5 3449/4885DRD4 3777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.